ALIM Alimera Sciences Inc

Price (delayed)

$5.54

Market cap

$38.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.04

Enterprise value

$72.42M

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or ...

Highlights
Alimera Sciences's gross profit has increased by 28% YoY
The equity is up by 28% year-on-year
The EPS has plunged by 58% from the previous quarter but it has grown by 27% YoY
Alimera Sciences's net income has shrunk by 53% QoQ but it has increased by 14% YoY
Alimera Sciences's quick ratio has decreased by 40% QoQ and by 21% YoY

Key stats

What are the main financial stats of ALIM
Market
Shares outstanding
7M
Market cap
$38.8M
Enterprise value
$72.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.65
EV/EBIT
N/A
EV/EBITDA
39.72
EV/Sales
1.21
Earnings
Revenue
$59.71M
EBIT
-$807,000
EBITDA
$1.82M
Free cash flow
-$7.62M
Per share
EPS
-$1.04
Free cash flow per share
-$1.09
Book value per share
-$1.23
Revenue per share
$8.54
TBVPS
$5.65
Balance sheet
Total assets
$49.93M
Total liabilities
$58.53M
Debt
$43.6M
Equity
-$8.6M
Working capital
$17.75M
Liquidity
Debt to equity
-5.07
Current ratio
2.04
Quick ratio
1.69
Net debt/EBITDA
18.44
Margins
EBITDA margin
3.1%
Gross margin
88%
Net margin
-11.2%
Operating margin
-3.2%
Efficiency
Return on assets
-11.6%
Return on equity
N/A
Return on invested capital
-1.4%
Return on capital employed
-2.5%
Return on sales
-1.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALIM stock price

How has the Alimera Sciences stock price performed over time
Intraday
-1.77%
1 week
3.75%
1 month
-3.15%
1 year
-40.43%
YTD
7.99%
QTD
-1.07%

Financial performance

How have Alimera Sciences's revenue and profit performed over time
Revenue
$59.71M
Gross profit
$52.57M
Operating income
-$1.92M
Net income
-$6.68M
Gross margin
88%
Net margin
-11.2%
Alimera Sciences's net income has shrunk by 53% QoQ but it has increased by 14% YoY
ALIM's operating margin has soared by 52% YoY
ALIM's net margin has dropped by 51% since the previous quarter but it is up by 32% year-on-year
The operating income is up by 39% year-on-year

Growth

What is Alimera Sciences's growth rate over time

Valuation

What is Alimera Sciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.65
EV/EBIT
N/A
EV/EBITDA
39.72
EV/Sales
1.21
The EPS has plunged by 58% from the previous quarter but it has grown by 27% YoY
The equity is up by 28% year-on-year
The stock's P/S is 46% less than its 5-year quarterly average of 1.2 and 7% less than its last 4 quarters average of 0.7
The revenue rose by 26% year-on-year

Efficiency

How efficient is Alimera Sciences business performance
ALIM's ROIC has plunged by 156% from the previous quarter but it has soared by 67% YoY
The ROS has plunged by 156% from the previous quarter but it has soared by 73% YoY
Alimera Sciences's return on assets has shrunk by 51% QoQ but it has increased by 28% YoY

Dividends

What is ALIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALIM.

Financial health

How did Alimera Sciences financials performed over time
Alimera Sciences's total assets is 15% less than its total liabilities
Alimera Sciences's quick ratio has decreased by 40% QoQ and by 21% YoY
The current ratio has declined by 39% since the previous quarter and by 25% year-on-year
The debt to equity has soared by 70% from the previous quarter but it has contracted by 35% YoY
The equity is up by 28% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.